Cardiff Oncology, Inc. (CRDF) - 10-K Summary
Business Context and Reporting Period
Company: Cardiff Oncology, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Cardiff is a clinical-stage biotechnology company developing onvansertib, an oral, highly selective Polo-like Kinase 1 (PLK1) inhibitor. The company focuses on combination therapies for RAS-mutated metastatic colorectal cancer (mCRC), metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple-negative breast cancer (TNBC). The company operates in a single segment and has no commercial product revenue from onvansertib to date.
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Revenues | $683 | $488 |
| Net Loss | $(45,431) | $(41,441) |
| Net Loss Attributable to Common Stockholders | $(45,455) | $(41,465) |
| Research & Development Expenses | $36,852 | $32,857 |
| Selling, General & Administrative Expenses | $12,482 | $13,043 |
| Cash, Cash Equivalents & Short-Term Investments | $91,746 | $74,823 |
| Working Capital | $81,626 | $66,972 |
| Accumulated Deficit | $(384,179) | $(339,541) |
Note: Revenue consists of royalty income from legacy intellectual property licenses unrelated to onvansertib.
Material Changes vs. Prior Period
- Revenue Growth: Royalty revenues increased by approximately 40% ($0.2 million) year-over-year, driven by licensee sales activities.
- Operating Expenses: Total operating expenses increased by $3.4 million to $49.3 million.
- R&D: Increased by $4.0 million, primarily due to higher clinical trial costs and outside services for onvansertib development, and a 15% increase in R&D headcount.
- SG&A: Decreased by $0.6 million, driven by lower insurance costs and the absence of a severance expense recorded in the prior year.
- Liquidity: Cash and short-term investments increased by approximately $16.9 million, bolstered by a $40 million gross proceeds registered direct offering in December 2024 and $16 million in net proceeds from an at-the-market offering.
- Net Loss: Increased by $4.0 million due to higher R&D spend, partially offset by a decrease in interest income ($3.3 million in 2024 vs. $4.1 million in 2023).
Guidance, Outlook, and Risks
Clinical Progress & Outlook:
- CRDF-004 (First-Line mCRC): Interim data presented in December 2024 showed an Objective Response Rate (ORR) of 57% for all onvansertib patients vs. 33% for the control arm. The 30mg dose showed a 64% ORR. The company plans to initiate a Phase 3 registrational trial (CRDF-005) contingent on these results.
- Other Programs: Enrollment is ongoing for investigator-initiated trials in mPDAC, SCLC, and TNBC.
- Capital Runway: Management projects sufficient capital resources to fund operations into the first quarter of 2027.
Key Risks & Contingencies:
- Capital Requirements: The company has an accumulated deficit of $384.2 million and expects to incur substantial losses for the foreseeable future. Continued access to capital markets is critical.
- Clinical Uncertainty: Onvansertib is in early clinical stages; there is no guarantee of regulatory approval or commercial success.
- Intellectual Property: The company relies on a license from Nerviano Medical Sciences; a material breach could result in termination of rights.
- Legal: A stockholder class action filed in May 2024 was mooted and dismissed in June 2024, with the company agreeing to pay $400,000 in legal fees.
Investor Verification Checklist
- Cash Runway: Verify the $91.7 million cash balance and the projection to fund operations into Q1 2027 against current burn rates.
- CRDF-004 Data: Review the full interim data release for the Phase 2 mCRC trial to assess the statistical significance of the 57% ORR and the safety profile of the 30mg dose.
- Phase 3 Timeline: Confirm the timeline and design for the planned CRDF-005 Phase 3 trial and FDA agreement on endpoints.
- Dilution Risk: Monitor future equity issuances required to fund the Phase 3 trial, given the company's history of raising capital via registered direct offerings and at-the-market sales.
- Patent Portfolio: Review the expiration dates of the Nerviano license (2027-2030) and the newly issued U.S. Patent No. 12,144,813 (expires no earlier than 2043) covering the bevacizumab-naïve combination.